Canadian marijuana titan Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB) together with 22nd Century Group, Inc. (NASDAQ: XXII) will license biosynthesis intellectual property to Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON). The licensed intellectual property is designed to help advance the research and development of the biosynthesis of cannabinoids.
What is biosynthesis?
Biosynthesis is a process common in the pharmaceutical industry, which involves using living micro-organisms to convert simple substances into complex compounds. Through biosynthesis, cannabinoids – particularly those that are rare such as cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN) – are expected to be produced efficiently and reliably at high levels of purity.
"We are deeply interested in the evolution of cannabinoids, and …